Celadon Pharmaceuticals PLC - London-based pharmaceutical company, focused on cannabis-based medicines - Says the provider of its committed credit facility has transferred an additional £147,000 under the £1.0 million draw down request. The company expects to receive the outstanding £103,000 during January. Celadon says receipt of these funds along with expected cash receipts from customers and continuing to work with creditors gives the company sufficient working capital up to March.

Current stock price: 14.00 pence, down 6.7%

12-month change: down 88%

Copyright 2025 Alliance News Ltd. All Rights Reserved.